BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 33888515)

  • 1. National Survey of Patient Factors Associated with Colorectal Cancer Screening Preferences.
    Zhu X; Parks PD; Weiser E; Fischer K; Griffin JM; Limburg PJ; Finney Rutten LJ
    Cancer Prev Res (Phila); 2021 May; 14(5):603-614. PubMed ID: 33888515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barriers to utilization of three colorectal cancer screening options - Data from a national survey.
    Zhu X; Parks PD; Weiser E; Jacobson DJ; Limburg PJ; Finney Rutten LJ
    Prev Med Rep; 2021 Dec; 24():101508. PubMed ID: 34401220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical Outcomes.
    Fendrick AM; Fisher DA; Saoud L; Ozbay AB; Karlitz JJ; Limburg PJ
    Cancer Prev Res (Phila); 2021 Sep; 14(9):845-850. PubMed ID: 34021023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alaska Native Patient and Provider Perspectives on the Multitarget Stool DNA Test Compared With Colonoscopy for Colorectal Cancer Screening.
    Redwood DG; Blake ID; Provost EM; Kisiel JB; Sacco FD; Ahlquist DA
    J Prim Care Community Health; 2019; 10():2150132719884295. PubMed ID: 31646933
    [No Abstract]   [Full Text] [Related]  

  • 5. Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening.
    Engel-Nitz NM; Miller-Wilson LA; Le L; Fisher DA
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):843-852. PubMed ID: 37462667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health Care Provider Characteristics Associated With Colorectal Cancer Screening Preferences and Use.
    Finney Rutten LJ; Parks PD; Weiser E; Fan C; Jacobson DJ; Jenkins GD; Zhu X; Griffin JM; Limburg PJ
    Mayo Clin Proc; 2022 Jan; 97(1):101-109. PubMed ID: 34920895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Multitarget Stool DNA Testing vs Colonoscopy or Fecal Immunochemical Testing for Colorectal Cancer Screening in Alaska Native People.
    Redwood DG; Dinh TA; Kisiel JB; Borah BJ; Moriarty JP; Provost EM; Sacco FD; Tiesinga JJ; Ahlquist DA
    Mayo Clin Proc; 2021 May; 96(5):1203-1217. PubMed ID: 33840520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
    Ladabaum U; Mannalithara A
    Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients.
    Prince M; Lester L; Chiniwala R; Berger B
    World J Gastroenterol; 2017 Jan; 23(3):464-471. PubMed ID: 28210082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives.
    Hathway JM; Miller-Wilson LA; Jensen IS; Ozbay B; Regan C; Jena AB; Weinstein MC; Parks PD
    J Med Econ; 2020 Jun; 23(6):581-592. PubMed ID: 32063100
    [No Abstract]   [Full Text] [Related]  

  • 11. Trends in Colorectal Cancer Screening from the National Health Interview Survey: Analysis of the Impact of Different Modalities on Overall Screening Rates.
    Ebner DW; Finney Rutten LJ; Miller-Wilson LA; Markwat N; Vahdat V; Ozbay AB; Limburg PJ
    Cancer Prev Res (Phila); 2024 Jun; 17(6):275-280. PubMed ID: 38561018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colonoscopy Findings in FIT+ and mt-sDNA+ Patients versus in Colonoscopy-only Patients: New Hampshire Colonoscopy Registry Data.
    Anderson JC; Robinson CM; Hisey W; Limburg PJ; Butterly LF
    Cancer Prev Res (Phila); 2022 Jul; 15(7):455-464. PubMed ID: 35378546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using a hypothetical scenario to assess public preferences for colorectal surveillance following screening-detected, intermediate-risk adenomas: annual home-based stool test vs. triennial colonoscopy.
    Bonello B; Ghanouni A; Bowyer HL; MacRae E; Atkin W; Halloran SP; Wardle J; von Wagner C
    BMC Gastroenterol; 2016 Sep; 16(1):113. PubMed ID: 27618798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
    Sharma T
    Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colorectal cancer screening preferences among physicians and individuals at average risk: A discrete choice experiment.
    Heidenreich S; Finney Rutten LJ; Miller-Wilson LA; Jimenez-Moreno C; Chua GN; Fisher DA
    Cancer Med; 2022 Aug; 11(16):3156-3167. PubMed ID: 35315224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPV and Detection Rate of mt-sDNA Testing, FIT, and CT Colonography for Advanced Neoplasia: A Hierarchic Bayesian Meta-Analysis of the Noninvasive Colorectal Screening Tests.
    Pickhardt PJ; Correale L; Hassan C
    AJR Am J Roentgenol; 2021 Oct; 217(4):817-830. PubMed ID: 33703913
    [No Abstract]   [Full Text] [Related]  

  • 18. Early Adoption of a Multitarget Stool DNA Test for Colorectal Cancer Screening.
    Finney Rutten LJ; Jacobson RM; Wilson PM; Jacobson DJ; Fan C; Kisiel JB; Sweetser S; Tulledge-Scheitel SM; St Sauver JL
    Mayo Clin Proc; 2017 May; 92(5):726-733. PubMed ID: 28473037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population.
    Fisher DA; Karlitz JJ; Jeyakumar S; Smith N; Limburg P; Lieberman D; Fendrick AM
    J Med Econ; 2021; 24(1):654-664. PubMed ID: 33902366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Replacing the Guaiac Fecal Occult Blood Test With the Fecal Immunochemical Test Increases Proportion of Individuals Screened in a Large Healthcare Setting.
    Akram A; Juang D; Bustamante R; Liu L; Earles A; Ho SB; Wang-Rodriguez J; Allison JE; Gupta S
    Clin Gastroenterol Hepatol; 2017 Aug; 15(8):1265-1270.e1. PubMed ID: 28167157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.